TABLE 3.
Improvement in Efficacy Assessments From Baseline to Week 5
| Efficacy Assessment | Placebo Plus Stimulant (n = 95) | CLON-XR Plus Stimulant (n = 102) | P |
|---|---|---|---|
| ADHD-RS-IV, mean (SD) | |||
| Total change | −11.5 (12.2) | −15.7 (12.3) | .009 |
| Inattention subscale | −5.8 (6.8) | −7.8 (6.8) | .017 |
| Hyperactivity/impulsivity subscale | −5.8 (6.3) | −7.9 (6.7) | .014 |
| CPRS, mean (SD) | |||
| Total change | −27.1 (38.2) | −40.2 (41.4) | .017 |
| Hyperactivity subscale | −3.8 (5.7) | −5.8 (6.5) | .017 |
| Oppositional subscale | −3.6 (6.3) | −5.1 (6.6) | .062 |
| CGI-S, mean (SD) | −1.2 (1.3) | −1.5 (1.2) | .021 |
| CGI-I, mean (SD) | 3.0 (1.2) | 2.5 (1.2) | .006 |
| PGA, mean (SD) | 3.4 (1.4) | 2.7 (1.3) | .001 |